Strides Pharma Science Limited has informed the Exchange about Transcript of Earnings Call pertaining to audited Financial Results of the Company for the quarter and financial year ended March 31, 2026
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Strides Pharma reported FY26 revenue of INR4,858.7 crore (6.4% YoY growth), with US business at $284 million impacted by a weak flu season. The company achieved its highest-ever EBITDA of INR925 crore (19% margin, +140 bps) and operational PAT of INR518 crore (50% growth), crossing the INR500 crore mark for the first time. Ex-US markets delivered robust 21% growth and now contribute nearly 50% of Q4 revenue, marking a structural shift away from single-market dependency. EBITDA grew at ~26% CAGR over 3 years while margins expanded 400 bps. The company reduced net debt by INR197 crore on constant currency basis, with net debt-to-EBITDA improving from 1.9x to 1.55x. Q4 margins were impacted by ~INR20 crore additional logistics costs due to geopolitical factors. The Board recommended a dividend of INR5 per share.
The strong profitability trajectory with 50% PAT growth and improving margins demonstrates operational leverage is working. The Ex-US diversification strategy is delivering faster than expected, reducing US dependency risk. However, the stock may see limited upside near-term as US recovery is expected only from H2 FY27.